Browse diseases

…ffuse large B-cell lymphoma, n=249; follicular lymphoma, n=107; Hodgkin lymphoma, n=96, stomach cancer, n=90; lung cancer, n=49; others, n=196).…

…thods We conducted a retrospective analysis of samples from 111 melanoma patients treated with anti-PD-1 therapy to quantify PD-1/PD-L1 …

…monotherapy and is now an FDA-approved combinatorial regimen in melanoma. We recently reported that PD1/LAG3 synergized to drive CD8 T c…

…e, 33.7 months by RECIST 1.1) in patients with anti-PD-1-failed melanoma, with mainly grade 1/2 constitutional-type side effects. The tr…

…vaccination induced strong immune activation in PD-1 refractory melanoma. All patients showed increased immune infiltration within the t…

…ckpoint blockade (ICB) tumor responses in colorectal cancer and melanoma mouse models.Results Animals exposed to chronic UVR exhibit dec…

…a, colon and prostate cancer, while a reduced SIR was found for lung cancer. Positive, but not statistically significant excess risks were …

…ons We here show that response and toxicity to cICB in advanced melanoma are driven by distinct immune features evident after only one c…

…by SEP, though it may be associated with sedentary occupations. Melanoma presents the strongest SEP gradient, with higher incidence in m…

…warranting targeted prevention and surveillance. In particular, melanoma risk underscores the need to minimise both occupational and rec…

…ving CPI was 7% (535 patients). The highest incidence was among melanoma patients receiving combination therapy of ipilimumab and nivolu…

… Among 259 patients (53% male, median age 63), cancers included melanoma (43%), renal (19%), lung (16%) and others. ICI regimens include…